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Introduction
Prostate cancer is the most commonly diagnosed malignancy of men. 1 Its progression may be accompanied by acquisition of androgen independence, a poor diagnostic indicator associated with a more metastatic phenotype. 2 Transformed cells depend on the activation of survival signaling pathways including the Ras/Raf/MEK/ERK and PI 3-kinase/Akt/mTOR pathways. Increased expression of the Ras/Raf/MEK/ERK pathway is associated with hormone-independent prostate cancer. 2 In response to the binding of growth factors, cytokines, and hormones to cell surface receptors, the level of Ras-guanosine triphosphate (GTP) increases, which directly binds and recruits cytosolic dimers of Raf kinases to the plasma membrane. The activated Raf assembles MAPK signaling complexes at the plasma membrane which initiate the activation of MEK by Raf and subsequently phosphorylation of ERK by MEK. The activated ERK dissociates 10 JNKs are a group of MAPKs that regulate apoptosis, proliferation, and survival signaling. Sustained JNK activation promotes apoptosis by both transcription-dependent and -independent mechanisms. JNK activates p53 by catalyzing its phosphorylation. JNK also phosphorylates and activates pro-apoptotic Bcl-2 family members and these inactivate prosurvival Bcl-2 family members. The subsequent liberation of the downstream effectors BAX and BAK elicits outer mitochondrial membrane
We have previously shown that treatment of prostate cancer and melanoma cells expressing GRp78 on their cell surface with antibody directed against the COOh-terminal domain of GRp78 upregulates and activates p53 causing decreased cell proliferation and upregulated apoptosis. In this report, we demonstrate that treatment of 1-LN prostate cancer cells with this antibody decreases cell surface expression of GRp78, akt Thr308 and akt ser473 kinase activities and reduces phosphorylation of FOXO, and GsK3β. This treatment also suppresses activation of eRK1/2, p38 MapK and MKK3/6; however, it upregulates MKK4 activity. JNK, as determined by its phosphorylation state, is subsequently activated, triggering apoptosis. Incubation of cells with antibody reduced levels of anti-apoptotic Bcl-2, while elevating pro-apoptotic BaD, BaX and BaK expression as well as cleaved caspases-3, -7, -8 and -9. silencing GRp78 or p53 gene expression by RNai prior to antibody treatment abrogated these effects. We conclude that antibody directed against the COOh-terminal domain of GRp78 may prove useful as a pan suppressor of proliferative/survival signaling in cancer cells expressing GRp78 on their cell surface.
which bind to the same region in the NH 2 -terminal domain of GRP78 as does α 2 M*. 36 We have shown that treatment of 1-LN, DU145 prostate cancer cells and A375 melanoma cancer cells, which expression GRP78 on their cell surface, with antibodies directed against the COOH-terminal domain of GRP78 significantly elevates p53 levels, inhibits DNA synthesis and cellular proliferation, while triggering apoptosis. 31 Silencing p53 or GRP78 gene expression by RNAi abrogated antibody-induced increase in p53 protein levels. 31 Since Akt is a key mediator of GRP78-induced cell survival and proliferative effects, we have studied the effects of downregulating cell surface GRP78 activation with antibody directed against the COOH-terminal domain of GRP78 on Akt activation and its downstream signaling: We demonstrate that this antibody: (1) downregulates cell surface GRP78 and Akt activation; (2) downregulates expression of BCl-2, FOXO1, GSK3β and XIAP; (3) increases the expression of PUMA, NOXA, BAD and BAX; and (4) causes an enhanced release of cytochrome C and activation of caspases. Silencing GRP78 or p53 gene expression by RNAi reversed these antibodyinduced effects.
Results

Anti-GRP78 antibody downregulates cell surface GRP78 and Akt
Thr-308 and Akt Ser-473 kinases in 1-LN cells. Antibodies directed against the COOH-terminal domain of GRP78 abrogate ligand-induced autophosphorylation of GRP78 and decrease the total cellular pool of GRP78. 31 The former effect is essential for activating pro-survival and anti-apoptotic signaling, while the latter effect decreases the ability of UPR to cope with cellular stresses. In the present study, we demonstrate that anti-CTD antibody downregulates cell surface expression of GRP78 by over 50% compared to α 2 M*-treated cells (Fig. 1) . This severely depleted expression of GRP78 on the cell surface together with decreased autophosphorylation 31 should affect receptor-mediated activation of downstream signaling. We, therefore, next studied the activation of Akt kinases in 1-LN cells incubated with anti-CTD antibody. Stimulation of 1-LN cells with α 2 M* increased Akt and Akt Ser-473 kinase activities as determined by the phosphorylation of the respective Akt kinase substrate peptides ( Fig. 2A) . α 2 M*-induced increase in Akt Ser-473 kinase activity was noticeably higher than that of Akt Thr-308 kinase activity in these cells ( Fig. 2A) . Pretreatment of cells with anti-CTD antibody significantly reduced α 2 M*-induced activation of Akt and Akt Ser-473 kinases to a comparable extent ( Fig. 2A) . In these antibody-treated cells activation of Akt kinases was lower than observed in cells treated with buffer (Fig. 2) . Since activation of Akt is a consequence of phosphorylation of Thr 308 and/ or Ser 473 , we employed western blotting to study the effects of anti-GRP78 antibody pre-treatment of cells on α 2 M*-mediated Akt phosphorylation. As expected, there was a decrease in the level of phosphorylation of these residues which parallels the loss of kinase activities described above (Fig. 2B) . There is, however, no decrease in the level of Akt protein.
Upregulated expression of PTEN in 1-LN cells treated with anti-GRP78 antibody. Akt kinase activity is negatively regulated permeabilization, release of cytochrome C, and activation of caspases culminating in cell death. ASK1 activates both p38 MAPK and JNK by directly phosphorylating MKK3/6 and MKK4/7, respectively. [11] [12] [13] [14] [15] [16] [17] [18] Thus, the coordinated regulation of p38 MAPK and JNK is a complex process which is critical to the pro-and anti-survival balance in tumors.
Akt is a Ser/Thr kinase that plays a vital role in cellular survival and proliferation. Akt activation occurs in response to multiple extracellular signals acting through Tyr kinase or G-protein coupled receptors. 19, 20 These receptors activate phosphatidyl-3-kinase (PI 3-kinase) which phosphorylates membrane phosphatidy linositol 4,5-bisphosphate to generate phosphatidylinositol-3,4,5-trisphosphate. The latter acts as a second messenger for a variety of pathways. This event promotes recruitment of Akt from the cytoplasm to the cellular membrane where phosphoinositidedependent kinase 1 phosphorylates Akt at Thr 308 and mTOR C2 phosphorylates Akt at Ser 473 . 21, 22 The tumor suppressor PTEN, a dual lipid/protein phosphatase, is frequently inactivated in human cancers and this results in hyperactivation of Akt. [23] [24] [25] [26] [27] [28] Deficiency of Akt in PTEN +/-mice is sufficient to markedly attenuate the development of high grade prostate intraepithelial neoplasia and endometrial carcinoma. 26 The levels of PTEN expression inversely correlate with Akt phosphorylation at Ser 473 , but not at Thr 308 . 27 Hyperactivation of Akt kinases is one of the most common occurrences in human malignancies and is observed in more than 50% of prostate carcinomas. Akt enhances cell survival by blocking the functions of proapoptotic proteins. Akt phosphorylates and inactivates BAD and blocks FOXO-mediated transcription of target genes that promote apoptosis and cell cycle arrest. Moreover, it phosphorylates MDM2 thus promoting its translocation to the nucleus where it degrades p53 blocking its transcriptional targets, PUMA and NOXA. Phosphorylation of GSK3 isoforms by Akt blocks its proapoptotic role. Akt also phosphorylates procaspase-9 blocking its activation and it activates NFκB promoting pro-proliferative signaling and inhibiting pro-apoptotic JNK signaling. 19, 20, 25 The molecular chaperone GRP78 is constitutively expressed, but its synthesis is induced by stressful conditions that perturb protein folding and assembly within the ER. 29 GRP78 plays a critical role in tumor development, progression, and resistance to chemotherapeutic agents. 29 Overexpression of GRP78 occurs in many tumors and this upregulated GRP78 correlates with an aggressive malignant phenotype and poor prognosis post treatment. 29 About 70% of human prostate cancers express high levels of GRP78 associating it with recurrence, development of castration resistance and poor survival. 29, 30 We have shown that binding of receptor-recognized forms of the plasma proteinase inhibitor α 2 -macroglobulin (α 2 M*) to cells expressing GRP78 on their surface results in activation of the Ras/ MAPK, PI 3-kinase/Akt, and PAK2-dependent signaling pathways. [31] [32] [33] [34] [35] Thus activated α 2 M* is a pro-growth, anti-apoptotic, and promigratory growth factor-like molecule. Silencing GRP78 gene expression by RNAi, inhibited MAPK and PI 3-kinasedependent signal transduction. [32] [33] [34] [35] Patients with serum autoantibodies to the NH 2 -terminal domain of GRP78 demonstrate a poor prognosis. These auto-antibodies are receptor agonists α 2 M*-treated cells (Fig. 3) . These results are supportive of the role of JNK signaling in tumor suppression.
Antibody directed against the COOH-terminal domain of GRP78 elevates pro-apoptotic proteins in 1-LN cells. Activated p53 can directly or indirectly modulate the expression of various proteins that control mitochondrial permeability, and therefore can modulate the release of mitochondrial proteins during apoptosis. [37] [38] [39] [40] [41] [42] p53 transcriptionally upregulates genes encoding BAX, FAS, death receptors, BID, PUMA, NOXA and Apaf1. p53 can also promote apoptosis through transcription-independent mechanisms. Mitochondria play a central role in apoptotic events through the release of pro-apoptotic factors. The Bcl-2 family of proteins comprising both anti-apoptotic (Bcl-2, BCXL) and pro-apoptotic (BAX, BAD, BAK, BID, BIM, NOXA, PUMA) members which integrate diverse cell death signals and regulate the integrity of the mitochondrial membrane. [37] [38] [39] [40] [41] [42] We have shown that treatment of cancer cells, which express GRP78 on their cell surface, with antibodies against COOH terminal domain of GRP78 caused a two-threefold increase in p53 protein levels. 31 This treatment also inhibited DNA synthesis and cell proliferation in 1-LN cancer cells. Here we show that incubation of 1-LN cells with anti-CTD antibody either alone or before α 2 M* treatment significantly elevated levels of PUMA, NOXA, BID and BIK compared to cells treated with α 2 M* alone by PTEN whose expression is inversely related to that of phosphorylated Akt in cancer cells. [25] [26] [27] [28] Loss of PTEN expression in experimental models leads to elevated activity of Akt kinases and increased cell survival. 37 PTEN regulates p53 protein stability through antagonizing the Akt/MDM2 pathway and in addition in a phosphatase-independent manner through interacting with p53. 37 In the nucleus, PTEN plays a role in maintaining high p53 acetylation levels which stabilize p53 protein. 37, 38 We next, therefore, analyzed by western blotting the expression of PTEN protein in 1-LN prostate cancer cells treated with anti-CTD antibody. The expression of PTEN in anti-CTD antibody treated 1-LN cells was significantly increased in comparison to cells treated with α 2 M* which showed none or negligible PTEN protein levels (Fig. 2C) . Thus, in addition to antibody-induced downregulation of Akt Thr308 and Akt Ser473 kinases, elevated levels of PTEN will limit activation of Akt further promoting apoptosis.
Antibody directed against the COOH-terminal domain of GRP78 downregulates activation of ERK1/2 and p38 MAPK in 1-LN cells. In response to diverse stimuli, MAPKs are activated through reversible phosphorylation of both Tyr and Thr residues by upstream kinases. They then phosphorylate a number of substrates and activate many signaling pathways which lead to diverse outcomes including proliferation or apoptosis. p38 MAPK tends to play a pro-oncogenetic role whereas JNK act as tumor suppressors. 39, 40 The p38 MAPK pathway promotes cell survival by activating anti-apoptotic mechanisms. In the MEK dependent pathway, activated ERK activates 90 kDa ribosomal s6 kinases, which phosphorylates and inactivates proapoptotic BAD. 90-kDa ribosomal s6 kinase also activates the transcription factor CREB which promotes cell survival by upregulating Bcl-2 expression. [5] [6] [7] [8] [9] [10] [11] The Ras-dependent MAPK pathway is one of the major signaling pathways in promoting mitogenesis and cellular proliferation in 1-LN cells treated with α 2 M*. In view of the greatly reduced receptor activation and cell surface expression of GRP78 observed when 1-LN prostate cancer cells are incubated with anti-CTD antibody, one anticipates downregulation of α 2 M*-induced ERK1/2 and p38 MAPK activation. As hypothesized, incubation of 1-LN cells with anti-CTD antibody either alone or with α 2 M* significantly decreased α 2 M*-induced increase in phosphorylation levels of ERK1/2 and p38 MAPK as well as upstream kinases MKK 3/6 of p38 MAPK (Fig. 3) . Thus it appears that downregulation of GRP78 also downregulates progrowth MAPK signaling in 1-LN prostate cancer cells.
Upregulation of JNK activity in 1-LN cells incubated with anti-GRP78 antibody. The JNK-dependent signaling pathway regulates pro-apoptotic events such as those dependent on BAX or BAK. 41, 42 In an earlier report we have shown that treatment of 1-LN cells with α 2 M* does not cause activation of JNK and its upstream kinases. 32 In view of the role of JNK in tumor suppression and the observed inhibition in 1-LN cells of DNA synthesis and cellular proliferation by anti-CTD antibody 31 we next examined the effect of this antibody on JNK as well as its upstream kinases compared to that observed with α 2 M* alone (Fig. 3) . JNK is activated by the upstream kinase MKK4. Incubation of 1-LN cells with anti-CTD antibody elevated phosphorylation of MKK4 and JNK compared to that observed in buffer or is supported by experiments where either GPR78 or p53 expression was suppressed by RNA interference profoundly reduced the antibody-induced increases in levels of PUMA, BAX, BAK and Apaf1 ( Fig. 4B and C) .
Anti-GRP78 antibody causes activation of caspases in 1-LN cells. Upregulation of proapoptotic proteins should result in activation of the initiator caspase-9 and the effectors caspase-3, and -7. As expected, a significant increase in levels of cleaved caspases-9, -3 and -7 as determined by western blotting (Fig.  6A) , and activation of caspase-3 and caspase-9 as determined by the enzyme assays (Fig. 6B) were observed in 1-LN prostate cancer cells treated with anti-CTD antibody as compared to cells treated with either buffer or α 2 M*. To examine the involvement of p53-initiated induction of the extrinsic pathway of apoptosis under our experimental conditions, we assayed cleaved caspase-8 by western blotting (Fig. 6) . A two-threefold increase in cleaved caspase-8 was observed in anti-CTD antibody-treated cells, while the levels of cleaved caspase-8 were low in α 2 M*-treated cells (Fig. 6) . Caspase-8 is a conserved asparatate-specific cysteine protease initiator of death receptor-mediated apoptosis. Caspase-8 also activates the intrinsic pathway through the cleavage of BID, a specific proximal substrate for caspase-8. Once cleaved, BID translocates from the cytosol to the outer mitochondrial membrane. Here it interacts with BAX and BAK, allowing them to oligomerize. This causes release of cytochrome C, thus activating the Apaf-l/caspase-9 apoptosome. Thus BID is an integrator factor of death receptor and mitochondrial apoptotic pathway. As demonstrated above, anti-CTD antibody treatment upregulates BID.
Attenuated expression of FOXO in 1-LN cells treated with anti-GRP78 antibody. Phosphorylation of the transcription factor FOXO by activated Akt promotes its export from the nucleus to the cytosol. As a consequence, FOXO is unavailable to target transcriptional factors involved in upregulating apoptotic pathway. 20 p-FOXO also interacts with the 14-3-3 protein, which serves to localize p-FOXO to the cytoplasm while also facilitating (Fig. 4A) . Likewise a two to threefold increase in protein levels of BAD, BAX and BAK was observed in 1-LN cells treated with anti-COOH-terminal domain antibody compared to cells treated with either buffer or α 2 M* (Fig. 5) . Increase in these apoptotic proteins causes mitochondrial permeabilization and release of cytochrome C, assembly of apoptosome Apaf 1, and activation of caspases-9, -3 and -7, respectively. As expected from these results, we observed an increased release of cytochrome c, and increased Apaf 1 levels with reduction in Bcl-2 in 1-LN cells after anti-CTD antibody treatment as compared to α 2 M*-treated cells ( Fig.  5A and B) . These results demonstrate that antibody directed against the COOH-terminal domain of GRP78 induces apoptosis by binding to cell surface-associated GRP78 and upregulating p53 which activates the intrinsic pathway of cell death. This view al. 49 employed a human monoclonal IgM antibody, designated SAM-6, to target a variant of GRP78 found on the cell surface of some tumors. Jakobsen et al. have isolated single chain human monoclonal antibodies from a phage display library which have a specificity for the COOH-terminal domain of GRP78, expressed on the surface of some breast cancer cells. 50 These antibodies, however, did not affect cell growth suggesting the importance of screening such antibodies for their anti-proliferative activity against tumors if they are to be employed therapeutically. In its nuclear export. 43 Since treatment of 1-LN prostate cancer cells with anti-GRP78 antibody significantly inhibited activation of Akt, levels of p-FOXO should decline. In fact, p-FOXO was significantly reduced in 1-LN cells treated with anti-CTD antibody compared to cells treated with α 2 M* (Fig. 7) .
Inhibition of GSK3β in 1-LN prostate cancer cells exposed to anti-GRP78 antibody. Activation of the PI 3-kinase pathway promotes GSK3β phosphorylation at Ser 9 thereby inhibiting its activity as an apoptosis-inducing kinase. 44 Several transcription factors are directly phosphorylated by activated GSK3β. The majority of these pro-apoptotic transcription factors are inhibited after phosphorylation. The level of phosphorylated GSK3β is markedly reduced in 1-LN cells treated with anti-CTD antibody as compared to cells treated with α 2 M* (Fig. 7) which suggests that GSK3β is involved in Akt-mediated cell survival.
Treatment of 1-LN cells with anti-GRP antibody downregulates XIAP. The IAPs are a family of intracellular antiapoptotic proteins that play a key role in cell survival by modulating death signaling pathways at post-mitochondrial levels. 45 Among IAPs, XIAP is the most potent inhibitor of caspases and apoptosis. 45 XIAP directly inhibits caspase-9. XIAP is a physiological substrate of activated Akt, thereby inhibiting its ubiquitination. 45 These effects reduce XIAP degradation and the increased levels of XIAP are associated with decreased caspase activity and apoptosis. Thus, in view of the greatly inhibited activation of Akt in anti-CTD antibody-treated 1-LN prostate cancer cells, one would expect reduced levels of XIAP under the experimental conditions and this indeed is observed (Fig. 6) .
Discussion
The endoplasmic reticulum (ER) is the site for synthesis, folding modifications and trafficking of secretory and cell surface proteins. The molecular chaperone GRP78, originally discovered as a protein inducible by glucose starvation, serves multiple functions in maintaining cellular homeostasis. GRP78 participates in ER protein translocation, chaperoning, ER-associated protein degradation, and ER calcium binding. 29, 30 Overexpression of GRP78 promotes tumor proliferation, metastasis and drug resistance. 29 Additionally, the localization of GRP78 to the cell surface of cancer cells is accompanied by more recently identified functions as a cell surface receptor for pro-proliferative and anti-apoptotic signaling. 32 In cancer cells, elevated glucose metabolism, increased glycolytic activity and poor vascularization in fast growing tumors lead to glucose starvation, low pH and hypoxia which induce ER stress and activation of GRP78 transcription. 29 In addition to ER stress, GRP78 transcription may be upregulated through other ER-stress independent mechanisms during tumor growth and these confer survival advantages for these tumors. [46] [47] [48] The aberrant activation of key intracellular signaling pathways is widely accepted as central to malignant transformation. Several approaches support the hypothesis that inhibiting multiple biological pathways that mediate tumor growth may be an effective therapeutic strategy. Among these, antigenspecific cellular immune therapy could provide control of cancer growth and improved patient survival. Previously Rauschert et directly by inhibiting apoptotic factors that are involved in the execution of apoptosis by the mitochondrial pathway; namely, BAD, caspase-9 and ASK1. Akt also influences transcriptional regulation by FOXO, p53 and other factors during apoptosis. Activation of ERK inhibits MAPK pathway apoptosis by phosphorylating BAD, among other mechanisms. Thus compromises of both PI 3-kinase/Akt and Ras-dependent signal transduction would promote mitochondrial apoptotic pathways.
In many tumors, constitutive activation of Akt occurs through mutations in the tumor suppressor PTEN. Overexpression of Akt kinases promotes anti-apoptotic signaling. [19] [20] [21] [22] [23] Akt phosphorylates and activates the mammalian target of rapamycin (mTOR) that plays a major role in regulating ribosome biogenesis, protein synthesis and cell size. Akt participates in cell cycle regulation by phosphorylating and inactivating cyclin-dependent kinase inhibitor p21 and inhibiting expression of p37/kip via FOXO. Disruption of the Akt gene in mice delays tumor growth, reduces lung metastasis, and reduces the proliferative capacity of tumors. 4, 5, [19] [20] [21] [22] [23] [24] [25] [46] [47] [48] [49] [50] [51] In summary, here we demonstrate that an antibody targeting the COOH-terminal domain of GRP78 is an antagonist against activation of cell surface-associated GRP78. This antagonism is characterized by suppression of the Ras-dependent MAPK and PI 3-kinase signaling pathways, but upregulation of JNK signaling. Based on the present and recently published studies, 31 several mechanisms may be proposed for the effects of antibodies targeting the COOH-terminal domain of cell surface GRP78. These antibodies suppress auto-phosphorylation of GRP78 required for an earlier report we demonstrated that treatment of 1-LN and DU146 prostate cancer cells and A375 melanoma cells, which express GRP78 on their surface, with antibodies against the COOH-terminal domain of GRP78 caused a two-threefold increase in p53 protein levels. 31 This treatment also inhibited DNA synthesis and cell proliferation in 1-LN cancer cells. In contrast, PC-3 prostate cancer cells, which do no express GRP78 on their surface, did not show these effects upon treatment with this antibody. However, after treatment with thapsigargin, PC-3 cells not only showed cell surface expression of GRP78, but also significantly increased p53 expression when treated with anti-GRP78 antibody. 31 Silencing GRP78 or p53 expression by RNAi nearly abolished p53 increase in 1-LN, DU145, and A375 cells by anti-CTD antibody.
The salient points of the present study are that treatment of 1-LN prostate cancer cells with anti-CTD antibody caused: (1) inhibition of phosphorylation of Akt at Thr 308 and Ser 473 residues, respectively; (2) downregulation of mitochondrial-mediated apoptosis as evidenced by decrease in the antiapoptotic Bcl-2 protein, increase in cytochrome C release, and increase in the levels of pro-apoptotic proteins BAD, BAX, PUMA, NOXA, BID, BAK and Apaf1; and (3) activation of caspases-3, -7, -8 and -9.
The data presented in this study demonstrate that treatment of 1-LN prostate cancer cells with antibodies against the COOHterminal domain of GRP78 inhibits Akt and MAPK activation, the two major anti-apoptotic and pro-proliferative signaling mechanism in many cancer cells. Activated Akt suppresses apoptosis prove useful in the treatment of patients with tumors expressing GRP78 on their cell surface.
Materials and Methods
Materials. Culture media were purchased from Invitrogen (Carlsbad, CA). α 2 M* was prepared as described previously. [32] [33] [34] [35] [36] Antibodies were procured against the COOH-terminal domain of GRP78, (Cat # SPA-826 from Stressgen Victoria, BC) which is designated anti-CTD antibody in this report. This antibody, at an IgG concentration of 200 µg/ml, was employed at a 1:200 dilution in these studies. [γ 33 P]-ATP (specific activity 3,000 Ci/mmol) was purchased from Perkin Elmer Life Sciences (Waltham, CA). The peptide substrates for Akt Ser-473 kinase (NH 2 -RRPHFPQFSYSA-COOH) and for Akt Thr-308 kinase (NH 2 -KTFCGTPEYLAPEVRR-COOH) were synthesized by Genemed (San Francisco, CA). The control peptide Zak3tide was from Upstate Cell Signaling Solutions (Charlottesville, VA). Antibodies against Akt1, p-Akt1
Thr-308 , p-Akt1 Ser-473 , p-ERK1/2, ERK1/2, p-p38 MAPK, 38 MAPK, p-JNK, JNK, p-MKK3/6, MKK3/6, p-MKK4, MKK4, Bcl-2, BAX, BID, BAD, GSK3β, XIAP and caspases-3, -9, -7 and -8 were procured from Cell Signaling Technology, Inc., (Beverly, MA). Antibody against PUMA, NOXA, and BIK were procured from Santa Cruz Biotechnology. Antibody against BAK were purchased from Nuenta. Other reagents of the highest available purity were procured locally.
Cancer cell lines. In a previous report on anti-CTD-induced apoptosis and p53 activation, we employed 1-LN, DU-145 and PC-3 prostate cancer cells and A-375 melanoma cells. 1-LN, DU145 and A375 cells express GRP78 on their cell surface whereas PC-3 does not, unless pretreated with thapsigargin. 31 The effect of anti-CTD antibody on apoptosis and p53 activation in this study were highly comparable, and were dependent upon the presence of GRP78 on the cell surface: therefore, in the current study, we have used only 1-LN prostate cancer cells as a representative cell line. The highly metastatic prostate carcinoma cell line 1-LN is derived from the less metastatic PC-3 cells and was a kind gift of Dr. Philip Walther (Duke University Medical Center, Durham, NC). 1-LN cells demonstrate a high level of GRP78 cell surface expression. [31] [32] [33] [34] Antibodies directed against the COOH-terminal domain of GRP78 are pro-apoptotic only when the tumor cells express GRP78 on their cell surface. 31 In our previous report, we observed no difference in response to anti-CTD antibody with respect to p53 upregulation or its modification by phosphorylation or acetylation; therefore, in the present study we employed 1-LN prostate cancer cells to examine the effect of antibody directed against the COOH-terminal domain of GRP78 on MAPK and Akt activation and its downstream cell proliferative and survival signaling. These cells were grown in 6-well plates (500 x 10 x 3/cells/well) to confluency in RPMI 1640 medium containing 10% FBS, 2 mM glutamine, 12.5 units/ml penicillin, 6.5 µg/ml streptomycin and 10 nM insulin in an humidified CO 2 (5%) incubator at 37°C. At about 90% confluency, the medium was aspirated, the monolayers washed agonist-mediated activation of cellular signaling cascades. They cause a reduction in the surface expression of GRP78, perhaps by promoting uptake and endosomal degradation. In addition, the previous studies demonstrate that ligating cell surface GRP78 by agonists activates transcription factors which increase the total pool of GRP78. 51 This does not occur when the antagonistic anti-GRP78 antibodies ligate the receptor. The resultant antiproliferative and pro-apoptotic activity of such an antibody could (NH 2 -GGEEEEYFELVKKKK-COOH) was used as the control peptide. The reactions were initiated by adding 50 µM ATP and 2 µCi of [γ 33 P]-ATP to each tube, the tubes were incubated for 30 min at 30°C with shaking, and the reactions stopped by adding 5 µl of 0.5 M EDTA to each tube. The tubes were centrifuged at 3,000 xg for 3 min and 40 µl of each supernatant was applied onto p81 Whatman phosphocellulose paper. Supernatants were allowed to dry, and the papers were washed four times by immersing them in a liter of phosphoric acid for 3 min. The papers were rinsed with acetone, and their radioactivity determined in a liquid scintillation counter.
Determination of cytosolic release of cytochrome C in 1-LN cells treated with anti-GRP78 antibody. 1-LN prostate cancer cells incubated overnight (2 x 10 6 cells/well) in RPMI 1640 medium were treated with buffer, α 2 M* (50 pM/10 min), anti-CTD antibody (1:200/30 min) or anti-CTD antibody (1:200/30 min) then α 2 M*. Reactions were terminated by aspirating the medium. The cells were harvested in PBS, transferred to centrifuge tubes, centrifuged at 800 rpm/5 min at 4°C. The pellet was suspended in a volume of buffer containing 20 mM HEPES, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA and proteinase inhibitor and incubated for 15 min on ice. Lysate was centrifuged at 10,000 xg for 15 min at 4°C, supernatant collected and protein with ice-cold HHBSS and a fresh volume of medium added to the monolayers.
Determination of cell surface expression of GRP78 in 1-LN cells treated with antibody directed against the COOHterminal domain of GRP78 by "on cell" western. In an earlier study we showed that incubation of 1-LN prostate cancer cells with anti-CTD antibody, significantly decreased total cellular GRP78 levels. 31 Here, we studied the cell surface expression of GRP78 in 1-LN cells treated with this antibody. Briefly, 1-LN cells were grown in RPMI 1640 medium with additions listed above in 24 well plates and incubated in an humidified incubator until the cells formed a uniform layer. The medium was aspirated, a fresh volume of the above medium added to each well followed by the additions of buffer, A blocking buffer containing 3% BSA and 5% non-immune goat serum in PBST was added to each well and cells incubated at room temperature with gentle shaking for 2 h. The blocking buffer was removed and cells incubated with antibody-CTD antibody (1:50) in PBST and cells incubated at 4°C overnight with gentle rotation. The reaction was stopped by aspirating the medium and washing the cells thrice with PBS followed by the addition of IRDYE 800 D-conjugated affinity purified antirabbit IgG (goat) in PBST and cells incubated for 60 min with shaking at room temperature. The medium was aspirated, cells washed twice with PBST and once with PBS, dried, imaged and cell surface expression of GRP78 quantified in a LICOOR Odyssey ® instrument according to the manufacturer's instructions. The Akt immunoprecipitates of 1-LN cells were obtained after treatment with buffer, α 2 M* (50 pM/10 min), anti-CTD antibody (1:200/30 min) or anti-CTD antibody then α 2 M*. The precipitates were washed sequentially with buffer supplemented with 0.5 M NaCl then buffer and 50 mM Tris·HCl, pH 7.4, supplemented with 1 mM DTT, 1 mM PMSF and 1 mM benzamidine by centrifugation at 2,500 x 5 min. Then 10 mM MgCl 2 , 1 mM dithiothreitol, 1 mM PMSF, 1 mM benzamidine and 20 µg/ml leupeptin was added followed by the addition of 30 dsRNA homologous in sequence to the target GRP78 mRNA (5'→3') AAA ATA CAG CAA TTA GTA AAG were chemically synthesized by Ambion. For making dsRNA the sense (5'→3', AAA ACA GCA AUU AGU AAAG) and antisense (5'→3') CUU UAC UAA UUG CUG UAU UTT oligonucleotides were annealed. The cancer cells were transfected 75 nM of annealed p53 dsRNA or dsGRP78 dsRNA and control cells were transfected with lipofectamine as described previously. 31 Forty-eight hours post transfection the control cells were stimulated with either buffer or anti-CTD antibody (1:200/30 min/37°C). Cells for the negative controls were transfected with scrambled dsRNA (75 nM/48 h) (Ambion, Austin, TX Cat #AM 4611) and then stimulated with anti-CTD antibody. Reactions were terminated by aspirating the medium and cells lysed in a volume of lysis buffer as described above. Protein contents of the respective lysates were determined and equal amounts of protein employed for determining p53 levels by western blotting as described above.
Measurement of caspase-3 and caspase-9 activities in 1-LN prostate cancer cells treated with anti-CTD antibody. 1-LN prostate cancer cells in 6-well plates (4 x 10 6 cells/well) in RPMI-S medium were treated overnight with: (1) vehicle; (2) α 2 M* (50 pM); (3) or anti-CTD antibody (1:200); and incubated at 37°C in a humidified CO 2 (5%) incubator. Reactions were terminated by aspirating the medium, a volume of ice-cold PBS added, cells scraped into separate new tubes, and washed with PBS by centrifugation at 10,000 xg at 4°C for 3 min. The respective pellets were lysed in a volume of lysis buffer B (50 mM HEPES, pH 7.4, 0.1% CHAPS, 0.1 mM EDTA and 5 mM DTT) and protein contents determined (52) . Caspase-3 and caspase-9 activities were assayed using the fluorogenic substrates AcDEVD-AMC for caspase-3 and AcLEHD-AMC for caspase-9 in 70 µl of reaction buffer containing 50 mM HEPES pH 7.4, 100 mM NaCl. 0.1% CHAPS, 10 mM DTT, 1 µM EDTA and 10% glycerol, 20 ul of lysate (20-25 µg protein) and 10 µl of respective substrates (300 uM) in 96 well plates. The reactions were carried out for 3 h at 37°C. Caspase activities were determined by quantifying the levels of free AMC released by caspase hydrolysis of substrates in a fluorescent plate reader (excitation λ = 360 nm and emission λ = 460 nm) and expressed as relative fluorescent units/mg protein.
contents determined. An equal amount of protein was employed for electrophoresis in all the samples. The protein bands on gels were transferred to membrane and membrane immunoblotted for cytochrome C.
Western blotting of signal pathway components in 1-LN cells treated with anti-GRP78 antibody. 1-LN prostate cancer cells incubated overnight in 6-well plates (3 x 10 6 cells/well), in RPMI medium described in foregoing sections were treated with buffer, α 2 M* (50 pM/10 min), anti-CTD antibody (1:200/30 min) or anti-CTD-antibody (1:200/30 min) then α 2 M* (50 pM/10 min). These times were chosen after performing time course studies to determine when the maximum effect was observed. The reactions were terminated by aspirating the medium, a volume of lysis buffer containing 50 mM Tris·HCl, pH 7.5, 120 mM NaCl, 1% (v/v) NP-40, 20 mM NaF, 1 mM sodium pyrophosphate, 0.1 mM sodium orthovanadate, 1 mM PMSF. 1 mM benzamidine and leupeptin (20 µg/ml) and cells lysed over ice for 5 min. The lysates were collected in microfuge tubes, DNA strands broken by passing the lysates through 27 gauge needle several times and centrifuged at 1,200 rpm at 4°C. The protein content of respective lysates in all the experiments were determined and equal amount of lysate protein in all the experiments described in the RESULTS section was used for electrophoresis on 10% gels in the presence of SDS. The protein bands on the gel were transferred to membrane and membrane immunoblotted with various antibodies described in the RESULTS section for different experiments. The protein bands on the membrane were visualized by ECF and Phosphorimaging. The membranes were reprobed for protein loading controls actin, as well as for unphosphorylated kinase proteins as a control for phosphorylated kinases. Where appropriate, data obtained from immunoblots are presented as ratios of protein/actin, protein/GAPDH or phosphorylated/unphosphorylated protein kinases.
Silencing GRP78 and p53 gene expression by RNAi and the effect of anti-GRP78 antibody on apoptotic protein levels in 1-LN cancer cells. To determine the target specificity of anti-CTD antibody, we silenced p53 gene expression by RNAi. 31 Annealed and validated siRNA of p53 ID # 106141 of the sense sequence (5→3') GGG UUA GUU UAC AAU CAG CTT and antisense sequence (5'→3') GCU GAU UGU AAA CUA AC CTT were chemically synthesized by Ambion.
